79 related articles for article (PubMed ID: 9818765)
1. Antimicrobial interactions of trovafloxacin and extended-spectrum cephalosporins or azithromycin tested against clinical isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
Johnson DM; Jones RN; Pfaller MA
J Antimicrob Chemother; 1998 Oct; 42(4):557-9. PubMed ID: 9818765
[No Abstract] [Full Text] [Related]
2. In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia.
Isenberg HD; Alperstein P; France K
Diagn Microbiol Infect Dis; 1999 Feb; 33(2):81-6. PubMed ID: 10091030
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the bactericidal activity of trovafloxacin and ciprofloxacin, alone and in combination with cefepime, against Pseudomonas aeruginosa.
McNabb J; Quintiliani R; Nightingale CH; Nicolau DP
Chemotherapy; 2000; 46(6):383-9. PubMed ID: 11053903
[TBL] [Abstract][Full Text] [Related]
4. In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents.
Ford AS; Baltch AL; Smith RP; Ritz W
J Antimicrob Chemother; 1993 Apr; 31(4):523-32. PubMed ID: 8390434
[TBL] [Abstract][Full Text] [Related]
5. Postantibiotic effect of trovafloxacin on Pseudomonas aeruginosa.
Boswell FJ; Andrews JM; Wise R
J Antimicrob Chemother; 1997 Jun; 39(6):811-4. PubMed ID: 9222052
[TBL] [Abstract][Full Text] [Related]
6. Activities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia.
Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1998 Aug; 42(8):2002-5. PubMed ID: 9687397
[TBL] [Abstract][Full Text] [Related]
7. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
Cunha BA; Qadri SM; Ueno Y; Walters EA; Domenico P
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
[TBL] [Abstract][Full Text] [Related]
8. Pseudomonas aeruginosa in vitro corneal isolate sensitivity to ofloxacin, ciprofloxacin, and trovafloxacin: a comparative study.
Song A; McCulley TJ; Lam BL; Feuer WJ; Miller D; Alfonso EC
Am J Ophthalmol; 2001 Jun; 131(6):795-6. PubMed ID: 11384579
[TBL] [Abstract][Full Text] [Related]
9. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
Wise R; Brenwald NP; Andrews JM; Boswell F
J Antimicrob Chemother; 1997 Apr; 39(4):447-52. PubMed ID: 9145816
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of trovafloxacin against Chlamydia pneumoniae.
Roblin PM; Kutlin A; Hammerschlag MR
Antimicrob Agents Chemother; 1997 Sep; 41(9):2033-4. PubMed ID: 9303410
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of ofloxacin, ciprofloxacin, and cefoperazone alone and in combination against Xanthomonas maltophilia.
Ristow TA; Peterson LR; Kahn JB
Drugs; 1995; 49 Suppl 2():246-9. PubMed ID: 8549319
[No Abstract] [Full Text] [Related]
12. Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.
Fitoussi F; Doit C; Geslin P; Bingen E
Antimicrob Agents Chemother; 1999 Oct; 43(10):2372-5. PubMed ID: 10508009
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations.
Krueger TS; Clark EA; Nix DE
Diagn Microbiol Infect Dis; 2001; 41(1-2):71-8. PubMed ID: 11687317
[TBL] [Abstract][Full Text] [Related]
14. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest.
Dembry LM; Farrel PA; Orcutt DR; Gerrity LA; Andriole VT
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():35-42. PubMed ID: 9222068
[TBL] [Abstract][Full Text] [Related]
15. Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia.
Zhang L; Li XZ; Poole K
J Antimicrob Chemother; 2001 Oct; 48(4):549-52. PubMed ID: 11581236
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of gemifloxacin and five other fluoroquinolones against defined isogenic mutants of Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus.
Schulte A; Heisig P
J Antimicrob Chemother; 2000 Dec; 46(6):1037-8. PubMed ID: 11102429
[No Abstract] [Full Text] [Related]
17. Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods.
Biedenbach DJ; Croco MA; Barrett TJ; Jones RN
Eur J Clin Microbiol Infect Dis; 1999 Jun; 18(6):428-31. PubMed ID: 10442421
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activities of newer quinolones against Pseudomonas species and Xanthomonas maltophilia isolated from patients with cancer.
Rolston KV; Messer M; Ho DH
Antimicrob Agents Chemother; 1990 Sep; 34(9):1812-3. PubMed ID: 2285297
[TBL] [Abstract][Full Text] [Related]
19. Postantibiotic effect of trovafloxacin against gram-positive and -negative organisms.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1998 Jun; 42(6):1503-5. PubMed ID: 9624503
[TBL] [Abstract][Full Text] [Related]
20. Serum bactericidal activity of trovafloxacin, in combination with cefepime or amikacin, in healthy volunteers.
Lubasch A; Ziege S; Brodersen B; Borner K; Koeppe P; Lode H
Clin Microbiol Infect; 2003 Jul; 9(7):670-7. PubMed ID: 12925107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
